Amgen announces resignation of two top executives

pharmafile | July 27, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Anthony C Cooper, R&D, biotech, retire, sean harper 

Amgen’s head of R&D, Dr Sean Harper, has announced that he is retiring from his current position as Executive Vice President of Research and Development, in order to pursue “opportunities in the early-stage biotechnology community”.

Dr Harper, aged 55, will be succeeded by Senior Vice President of Translational Sciences and Oncology, Dave Reese, who joined the company in 2005.

Since joining Amgen in 2002 as Vice President of Development, Dr Harper has assumed increasingly senior roles within the company. He eventually took on his current role as Executive Vice President of R&D in February 2012. Since expanding his responsibilities as R&D chief, Harper has led the company to achieve a number of product approvals for medicines in the areas of cardiovascular disease, kidney disease, oncology, and neuroscience.   

Dr Harper graduated with a medical degree from the University of California at San Francisco before completing internal medicine and gastroenterology training at the Massachusetts General Hospital. Prior to joining Amgen, Dr Harper, acted as Senior Director of Clinical Genomics at Merck Research Laboratories.

Anthony C. Hooper is also set to stand down from his role as Executive Vice President of Global Communications Operations. He will be succeeded by Bristol-Myers Squibb Chief Commercial Officer Murdo Gordon, in September of this year.

Amgen Chairman and Chief Executive Officer Robert A. Bradway said: “I would like to thank both Sean and Tony for the important contributions they have made to Amgen, each bringing their own vital experiences and skills. They leave the Company having established strong foundations within Research and Development and Global Commercial Operations for the future. It is a testament to their leadership and accomplishments that they have attracted such exceptional talent to succeed them.”

He added “I am looking forward to having Dave and Murdo join us in their new leadership roles. With their deep combined expertise, they will add meaningfully to helping advance Amgen’s mission of serving patients.

Related Content

Evotec and Dewpoint Therapeutics enter strategic partnership

Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content